Claims for Patent: 8,795,659

Summary for Patent: 8,795,659

Title:	Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
Abstract:	The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: ##STR00001## (I) wherein A.sup.+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.
Inventor(s):	Morgan; Lee R. (New Orleans, LA)
Assignee:	Dekk-Tec, Inc. (New Orleans, LA)
Application Number:	13/541,522
Patent Claims:	1. A compound of the formula ##STR00016## wherein A.sup.+ represents a conjugate acid of an amine selected from the group consisting of acyclic aliphatic amine substituted by one or more hydroxy groups, di-acyclicalkyl amine substituted by one or more hydroxy groups, tri-acyclicalkyl amine substituted by one or more hydroxy groups, di-cyclicalkyl amine, tri-cyclicalkyl amine; and X and Y independently represent leaving groups. 2. The compound of claim 1, wherein A.sup.+ is selected from the groups consisting of the conjugated acid of N-methyl-N-ethylamine, diethylamine, triethylamine, diisopropylethylamine, mono-, bis- or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, tris(hydroxymethyl)methylamine, N,N-dimethyl-N-(2-hydroxyethyl)amine, and tri-(2-hydroxyethyl)amine. 3. The compound of claim 1, wherein A.sup.+ is the conjugated acid of tris-(2-hydroxyethyl)amine. 4. The compound of claim 1, wherein X and Y are independently selected from the group consisting of halogens and sulfonates. 5. The compound of claim 1, wherein X and Y are halogen. 6. The compound of claim 1, wherein X and Y are chloride. 7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier. 8. The pharmaceutical composition of claim 7, wherein A.sup.+ is the conjugated acid of tris-(2-hydroxyethyl)amine. 9. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises a solution formulated for administration to a human subject. 10. The pharmaceutical composition of claim 7 further comprising a second compound. 11. The pharmaceutical composition of claim 10, wherein the second compound is selected from the group consisting of microtubule binding agents, DNA intercalators or cross-linkers, DNA synthesis inhibitors, DNA and/or RNA transcription inhibitors, enzyme inhibitors, gene regulators, enzymes, antibodies and angiogenesis inhibitors. 12. The pharmaceutical composition of claim 10, wherein the second compound is selected from the group consisting of paclitaxel, docetaxel, daunorubicin, cisplatin, carboplatin, oxaliplatin, colchicine, dolastatin 15, nocodazole podophyllotoxin, rhizoxin, vinblastine, vindesine, vinorelbine (navelbine), epothilones, mitomycins, bleomycin chlorambucil, carmustine, melphalan, mitoxantrone 5-fluoro-5'-deoxyuridine, camptothecin, topotecan, irinotecanetoposide, tenoposide, geldanamycin, methotrexate, adriamycin, actinomycin D, mifepristone, raloxifene, 5-azacytidine, 5-aza-2'-deoxycytidine, zebularine, tamoxifen, 4-hydroxytamoxifen, apigenin, rapamycin, angiostatin K1-3, L-asparaginase, staurosporine, genistein, fumagillin, endostatin, thalidomide and analogs thereof. 13. The pharmaceutical composition of claim 10, further comprising a third compound, wherein the third compound is selected from the group consisting of microtubule binding agents, DNA intercalators or cross-linkers, DNA synthesis inhibitors, DNA and/or RNA transcription inhibitors, enzyme inhibitors, gene regulators, enzymes, antibodies and angiogenesis inhibitors.

Details for Patent 8,795,659

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2024-10-25